Indivior PLC
Indivior develops, manufactures, and sells prescription drugs to treat opioid dependence and related disorders globally. Core products include SUBLOCADE injections, SUBOXONE Film/TABLET, and SUBUTEX Tablet for opioid use disorder. The company also offers OPVEE nasal spray for overdose reversal. Indivior is developing INDV-2000 for moderate to severe OUD and INDV-6001 with Alar Pharmaceuticals Inc.
Overview
Strengths
- The company has low debt. Net Debt to EBITDA Ratio is 0.05 and it is lower than the sector mean.
- EV/EBITDA (10.26) is lower than the sector mean (51.86).
- Strong EBITDA Margin of 23.57%.
Weaknesses
- With a depreciation Potential of -30.35%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (1429.51) is significantly higher than the sector mean (289.29).
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- The Price to Free Cash Flow ratio (571.81) is significantly higher than the sector mean.
Key Financial Data
| Indicator | Value |
|---|
| PER | 1405.8 |
| EV/EBITDA | 10.1 |
| Price/Free Cash Flow' | 562.3 |
| ROIC | -% |
| Net Debt/EBITDA | 0.1 |